172 related articles for article (PubMed ID: 33632875)
1. A Novel Antibody-IL15 Fusion Protein Selectively Localizes to Tumors, Synergizes with TNF-based Immunocytokine, and Inhibits Metastasis.
Corbellari R; Stringhini M; Mock J; Ongaro T; Villa A; Neri D; De Luca R
Mol Cancer Ther; 2021 May; 20(5):859-871. PubMed ID: 33632875
[TBL] [Abstract][Full Text] [Related]
2. Design and characterisation of a novel interleukin-15 receptor alpha fusion protein and analysis of interleukin-15 complexation.
Schmid AS; Neri D
PLoS One; 2019; 14(7):e0219313. PubMed ID: 31348785
[TBL] [Abstract][Full Text] [Related]
3. Tumor-targeting properties of novel immunocytokines based on murine IL1β and IL6.
Hess C; Neri D
Protein Eng Des Sel; 2014 Jun; 27(6):207-13. PubMed ID: 24795343
[TBL] [Abstract][Full Text] [Related]
4. The antibody-based delivery of interleukin-12 to the tumor neovasculature eradicates murine models of cancer in combination with paclitaxel.
Pasche N; Wulhfard S; Pretto F; Carugati E; Neri D
Clin Cancer Res; 2012 Aug; 18(15):4092-103. PubMed ID: 22693354
[TBL] [Abstract][Full Text] [Related]
5. Murine analogues of etanercept and of F8-IL10 inhibit the progression of collagen-induced arthritis in the mouse.
Doll F; Schwager K; Hemmerle T; Neri D
Arthritis Res Ther; 2013 Sep; 15(5):R138. PubMed ID: 24289726
[TBL] [Abstract][Full Text] [Related]
6. The antibody-mediated targeted delivery of interleukin-13 to syngeneic murine tumors mediates a potent anticancer activity.
Hess C; Neri D
Cancer Immunol Immunother; 2015 May; 64(5):635-44. PubMed ID: 25722088
[TBL] [Abstract][Full Text] [Related]
7. Antibody-mediated delivery of LIGHT to the tumor boosts natural killer cells and delays tumor progression.
Stringhini M; Mock J; Fontana V; Murer P; Neri D
MAbs; 2021; 13(1):1868066. PubMed ID: 33404287
[TBL] [Abstract][Full Text] [Related]
8. The dose-dependent tumor targeting of antibody-IFNγ fusion proteins reveals an unexpected receptor-trapping mechanism in vivo.
Hemmerle T; Neri D
Cancer Immunol Res; 2014 Jun; 2(6):559-67. PubMed ID: 24795141
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic efficacy of the F8-IL2 immunocytokine in a metastatic mouse model of lung adenocarcinoma.
Wieckowski S; Hemmerle T; Prince SS; Schlienger BD; Hillinger S; Neri D; Zippelius A
Lung Cancer; 2015 Apr; 88(1):9-15. PubMed ID: 25682318
[TBL] [Abstract][Full Text] [Related]
10. Novel antibody-cytokine fusion proteins featuring granulocyte-colony stimulating factor, interleukin-3 and interleukin-4 as payloads.
Schmid AS; Tintor D; Neri D
J Biotechnol; 2018 Apr; 271():29-36. PubMed ID: 29438784
[TBL] [Abstract][Full Text] [Related]
11. Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis.
Schwager K; Kaspar M; Bootz F; Marcolongo R; Paresce E; Neri D; Trachsel E
Arthritis Res Ther; 2009; 11(5):R142. PubMed ID: 19781067
[TBL] [Abstract][Full Text] [Related]
12. The antibody-based targeted delivery of interleukin-4 and 12 to the tumor neovasculature eradicates tumors in three mouse models of cancer.
Hemmerle T; Neri D
Int J Cancer; 2014 Jan; 134(2):467-77. PubMed ID: 23818211
[TBL] [Abstract][Full Text] [Related]
13. Potentiation of PD-L1 blockade with a potency-matched dual cytokine-antibody fusion protein leads to cancer eradication in BALB/c-derived tumors but not in other mouse strains.
De Luca R; Neri D
Cancer Immunol Immunother; 2018 Sep; 67(9):1381-1391. PubMed ID: 29971465
[TBL] [Abstract][Full Text] [Related]
14. A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo.
Villa A; Trachsel E; Kaspar M; Schliemann C; Sommavilla R; Rybak JN; Rösli C; Borsi L; Neri D
Int J Cancer; 2008 Jun; 122(11):2405-13. PubMed ID: 18271006
[TBL] [Abstract][Full Text] [Related]
15. Antibody-based targeting of interferon-alpha to the tumor neovasculature: a critical evaluation.
Frey K; Zivanovic A; Schwager K; Neri D
Integr Biol (Camb); 2011 Apr; 3(4):468-78. PubMed ID: 21225052
[TBL] [Abstract][Full Text] [Related]
16. Potency-matched Dual Cytokine-Antibody Fusion Proteins for Cancer Therapy.
De Luca R; Soltermann A; Pretto F; Pemberton-Ross C; Pellegrini G; Wulhfard S; Neri D
Mol Cancer Ther; 2017 Nov; 16(11):2442-2451. PubMed ID: 28716814
[TBL] [Abstract][Full Text] [Related]
17. Antibody-Based Targeted Delivery of Interleukin-22 Promotes Rapid Clinical Recovery in Mice With DSS-Induced Colitis.
Bootz F; Ziffels B; Neri D
Inflamm Bowel Dis; 2016 Sep; 22(9):2098-105. PubMed ID: 27482975
[TBL] [Abstract][Full Text] [Related]
18. IL15-Based Trifunctional Antibody-Fusion Proteins with Costimulatory TNF-Superfamily Ligands in the Single-Chain Format for Cancer Immunotherapy.
Beha N; Harder M; Ring S; Kontermann RE; Müller D
Mol Cancer Ther; 2019 Jul; 18(7):1278-1288. PubMed ID: 31040163
[TBL] [Abstract][Full Text] [Related]
19. An engineered 4-1BBL fusion protein with "activity on demand".
Mock J; Stringhini M; Villa A; Weller M; Weiss T; Neri D
Proc Natl Acad Sci U S A; 2020 Dec; 117(50):31780-31788. PubMed ID: 33239441
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of antibody-chemokine fusion proteins for tumor-targeting applications.
Hess C; Neri D
Exp Biol Med (Maywood); 2014 Jul; 239(7):842-852. PubMed ID: 24872435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]